A novel approach for ex-vivo expansion (EvE) of NK CD3−/CD16+/56+bright/dim subsets expressing increased inhibitory receptors from cryopreserved/thawed/expanded/recryopreserved/rethawed (CTECT) and cryopreserved/thawed/recryopreserved/rethawed/expanded (CTCTE) umbilical cord blood (UCB) using anti-CD3, IL-2, IL-7 and IL-12 (AB/CY)  by Ayello, J. et al.
should be discontinued, and calculations individualized for each
procedure.
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A NOVEL APPROACH FOR EX-VIVO EXPANSION (EVE) OF NK CD3-/
CD16/56BRIGHT/DIM SUBSETS EXPRESSING INCREASED INHIBITORY
RECEPTORS FROM CRYOPRESERVED/THAWED/EXPANDED/RECRYO-
PRESERVED/RETHAWED (CTECT) AND CRYOPRESERVED/THAWED/RE-
CRYOPRESERVED/RETHAWED/EXPANDED (CTCTE) UMBILICAL CORD
BLOOD (UCB) USING ANTI-CD3, IL-2, IL-7 AND IL-12 (AB/CY)
Ayello, J.1, Satwani, P.1, van de Ven, C.1, Simpson, L.L.1, Kurtzberg,
J.2, Cairo, M.S.1 1. Children’s Hospital of New York-Presbyterian,
Columbia University, New York, NY; 2. Duke University, Durham,
NC
CD56brightdimNK express killer-Ig-like receptors (KIR) and
C-lectin (NKG2), and natural cytoxicity receptors (NCR) involved
with tumor target recognition may play a role in ACI of malig-
nancies (Farag et al, Blood 100:1935, 2002). We compared expan-
sion, maturation and cell survival of CD3-/CD16/56,
CD56bright/dim, KIR inhibitory and C-lectin NK subsets in UCB
aliquots. Non-adherent cells were cultured in SF AIM-V alone or
with anti-CD3 (50 ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml) and
IL-12 (10 ng/ml) (AB/CY). The expanded population was analyzed
for expression of NK subsets (CD94, CD16, CD56bright/dim)
and NK receptors (KIR3DL1, KIR2DL1/S1, KIR2DL2 and
NKG2A) by ﬂow cytometry using CD16, CD56, NKBL1,
CD158a, CD158b, CD94 and NKG2A mAbs. Apoptotic markers
were determined by presence of Annexin V and PI. A signiﬁcant
increase in CD16/CD56bright /dim  and CD94/NKG2A ex-
pression was seen in CTECT and CTCTE in AB/CY compared to
AIM-V alone (CD16/56bright/CTECT: 11 1 vs 2.5 .3%, p
.05; CD16/CD56dim: 46  6 vs 27  2%, p  .03; CD16/
56bright/CTCTE: 9  2 vs 2  .2%, p  .05; CD16/CD56dim:
40  2 vs 27  3%, p  .01; CD94/NKG2A: CTECT: 17  3
vs 2  .9%, p  .001; CTCTE: 25  2 vs 8  3%, p  .001).
Signiﬁcant increases were seen in NK KIR receptors expression
(CD56bright/KIR3DL1 and CD56dim/KIR3DL1) when AB/CY
was compared to AIM-V (CTECT: 11  0.7 vs .4  .07%, p 
.0001; 4  0.1 vs 1.5  0.4%, p  .003; CTCTE: 7  2 vs 1  .3
%, p  .05; 8  1 vs 3  .8%, p  .01, respectively), CD56bright/
KIR2DL1/S1 and CD56dim/KIR2DL1/S1 (CTECT: 12  1 vs
3  .4%, p  .004; 41  2 vs 9  1%, p  .0002; CTCTE: 6 
.5 vs 2  .1%, p  .05; 22  8 vs 5  1, p  .01) and CD56bright/
KIR2DL2 and CD56dim/KIR2DL2 (CTECT: 14  .8 vs 2 
.2%, p  .0002 and 29  .9 vs 12  .4%, p  .0001; CTCTE:
14  2 vs 2  .1%, p  .05 and 25  7 vs 6  1%, p  .001,
respectively). To determine if the increase was secondary to in-
creased cell survival, CTECT and CTCTE AB/CY expanded
cultures showed minimal apoptosis compared to SF AIM-V (1.1 
3 vs 6 .5%, p .001; 5 1 vs 11 .6%, p .05). No signiﬁcant
difference between CTECT and CTCTE modalities was seen
except in CD94/NKG2A (p  .05) and CD56bright/KIR2DL2
(p  .05). These data suggest that CD16/CD56bright/dim NK
subsets expressing increased KIR and C-lectin receptors can be
EvE with AB/CY from CTECT or CTCTE UCB for possible use
in ACI for DLI after UCBT. In-vitro functional and in-vivo
xenotransplant animal studies are underway to further examine the
cytolytic activity of these UCB NK subsets.
26
EX VIVO EXPANSION OF IMMATURE AND MATURE T CELLS DERIVED
FROM UMBILICAL CORD BLOOD (UCB)
Staba, S.L., Crapnell, K.B., Hall, J.G., Reese, M., Kurtzberg, J. Duke
University Medical Center, Durham, NC
Introduction: Unrelated umbilical cord blood (UCB) is an effec-
tive source of allogeneic hematopoietic stem cells for transplanta-
tion therapy in patients lacking matched bone marrow donors.
Opportunistic infection is the major cause of mortality post trans-
plant, due in part to the immunologic naivete´ of the UCB T-cells.
We hypothesized that UCB derived immature and mature T-cells
could be expanded ex-vivo, and utilized a patient-derived skin
stromal layer with a supplemental cytokine cocktail to support the
growth of bulk UCB cells. The long term goal is to provide
UCB-derived adoptive immunotherapy in UCBT recipients.
Methods: Patient derived skin ﬁbroblasts were cultured in a media
of IMDM, 10% fetal calf serum and 10% horse serum for 14 days,
then irradiated to 5,000 cGy. Cryopreserved UCB cells were
thawed and cultured on this stromal layer in the same media
supplemented with a cytokine cocktail of interleukin-7 (IL-7) (10
ng/ml), ﬂt-3 ligand (10 ng/ml), and stem cell factor (50 ng/ml).
UCB cells were cultured with cytokines alone and skin alone as
controls. As a 2nd phase, interleukin-2 (IL-2) was added at day 14
for further expansion, with cells cultured for an additional 14 days
thereafter. Cell count, viability, and FACs analysis were per-
formed. Results: Gating on CD3, in cells cultured with both
skin stroma and cytokines mean fold increases of 6 in CD4, 11 in
CD8 and 34 in CD4/CD8 cells were seen. With cytokines
alone, mean fold increases were 3, 4 and 10 respectively. Minimal
expansion occurred with skin alone. With cytokines and IL-2,
mean fold increases were 4 in CD4, 4 in CD8 and 10 in
CD4/CD8 cells. Maximal expansion occurred with skin
stroma, the cytokine cocktail and IL-2, with mean fold increases of
9 in CD4, 11 in CD8 and 53 in CD4/CD8 cells. Results are
summarized in the table below. Conclusions: The expansion of
T-cells from unfractionated, red blood cell depleted, cryopreserved
UCB can be accomplished using a cytokine cocktail of IL-7, Flt 3
ligand and SCF over a patient derived, irradiated skin stromal
layer. Maximal expansion occurs with the addition of IL-2 and was
greatest in the immature CD4/CD8T-cell subset. We hypoth-
esize that this subset of T cells could serve as a target population
for adoptive immunotherapy, however further testing will deter-
mine the optimal cellular target and conditions for ex vivo expan-
sion and immunization. These cells could then be used to augment
immune reconstitution after UCBT.
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ISOLATION AND FUNCTIONAL INHIBITORY AFFECTS OF SPECIFIC PEP-
TIDES BOUND TO TYPE 2 DENDRITIC CELLS (DC2)
Rosenthal, H.S., Jaye, D.L., Cherry, E., Waller, E.K. Emory Univer-
sity, Atlanta, GA
Introduction: The impact of immunoregulatory type 1 (DC1)
and type 2 (DC2) dendritic cells in allogeneic hematopoetic pro-
genitor cell (HPC) transplantation has increased in interest. We
have shown that greater numbers of DC2s in allogeneic HPC
transplanted grafts has resulted in an increase in post-transplant
relapse and a reduction of graft vs host disease (GVHD). Isolation
of dendritic cell speciﬁc peptides thru phage display technology
provides a method of studying the immunoregulatory affects of
these cells and perhaps engineer grafts with anti-tumor affects.
Method: Random phage peptide libraries were incubated over-
night at 4° C with column enriched peripheral blood DC2 cells.
Unbound phage was removed by washing. FACS sorting of the
Lin-, CD123, HLA-Dr cells, further puriﬁed the DC2 popu-
lation. DC2 bound phage were removed from the cell surface,
eluted and puriﬁed. Three rounds of this phage selection process
(panning) were performed. A portion of the round 2 phage puri-
ﬁcation was incubated with enriched monocytes prior to incuba-
tion with DC2 cells to assist in eliminating phage that recognized
common epitopes on both cell types. Flow cytometry identiﬁed





Skin Alone (n  8) 0 0 0
Cytokines (n  10) 3 4 10
Cytokines  IL-2 (n  5) 4 4 10
Skin  Cytokines (n  10) 6 11 34
Skin  Cytokines  IL-2 (n  5) 9 12 53
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